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Abstract 
Background: Congenital bleeding disorders (CBD) are a group of 
coagulopathies with different clinical and laboratory features. The prevalence 
of these disorders in different parts of the world is variable. Iran as a country 
with a high rate of parental consanguinity has a high rate of CBDs. This study 
was to report the prevalence of these disorders in Kurdistan province, west of 
Iran. 
Methods and materials: This descriptive study was conducted on patients 
suspected of a congenital bleeding disorder referred to hemophilia center of this 
province for evaluation of underlying bleeding diathesis. Diagnosis and 
classification of disorders were made by routine and specific laboratory tests. 
Results: Out of 107 patients, 65.4% affected by common bleeding disorders 
(hemophilia A and B), 23.4% affected by rare bleeding disorders (RBDs) and 
11.2% had inherited platelet disorders. Factor VII deficiency (64%) was the 
most common RBDs and 9 patients had von Willebrand disease. Out of three 
patients with inherited platelet disorders, two had Glanzmann thrombasthenia. 
Conclusion: CBD pattern though has similar patterns with total pattern of the 
country, some of the inherited platelet disorders are more common in Kurdish 
province. Determination of prevalence and distribution of these disorders can 
improve health system planning and resource allocation. 
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bleeding disorders, inherited platelet disorders  
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Introduction 
Congenital bleeding disorders (CBDs) are a 
heterogeneous group of coagulopathies with various 
bleeding tendencies. Hemophilia A (HA), hemophilia 
B (HB) and von Willebrand's disease (vWD) are the 
most common which accounted for more than 90% of 
all CBDs (1). Other CBDs including factor (F) I, FII, 
FV, FVII, FX, FXI, FXIII, combined FV and FVIII, 
and combined vitamin K dependent factors 
deficiencies are rare bleeding disorders (RBDs) which 
account for 2% to 5% of all CBDs. The frequency of 
RBDs is varying between 1/500000 for FVII 
deficiency (FVIID) to 1/2000000 for FXIII (FXIIID) 
and FII deficiencies (FIID) (2). Inherited platelet 
function defects are another infrequent group of CBDs 
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that result from defects in platelet activation, adhesion, 
and aggregation (3). Although RBDs and inherited 
platelet disorders are rare, they are more frequent in an 
area such as Middle East countries with a high rate of 
consanguinity (2, 3). Iran has a high frequency of 
inherited bleeding disorder which can be related to an 
increased rate of parental consanguinity. Although 
some studies report the prevalence of CBDs in 
different regions of Iran, the precise distribution of 
these disorders is not established in all areas. Accurate 
data on the prevalence of these disorders in different 
regions of the country is necessary for health care 
programs. Therefore current study aimed to document 
the prevalence of CBDs in Kurdistan Province, west of 
Iran 
Methods 
Study subjects: this descriptive study was conducted 
on patients affected by CBDs who referred to 
hemophilia center in Kurdistan Province. This study 
was approved by the Ethics Research Committee 
(IR.MUK.REC.1398.301; No.1398.301), Kurdistan 
University of Medical Sciences, Sanandaj, Iran. The 
diagnosis was established based on family history, 
physical examination, clinical records and coagulation, 
and platelet function assays. Patients with a history of 
intake of any drugs affecting platelet function in the 
previous 4 weeks, with evidence of uremia, liver 
disease, dysproteinemias, acute leukemia, 
myeloproliferative disorders, and the myelodysplastic 
syndrome were excluded. Ethics Committee of 
Kurdistan University of Medical Sciences approved 
the study. Written consent was given from all patients 
or their parents. 
Study protocols: at the beginning, all patients were 
evaluated by routine tests including platelet count 
(Sysmex kx_21 hematology analyzer, Kobe, Japan), 
bleeding time (BT-modified Ivy’s method, normal 
range:3-8 minute), prothrombin time (PT, normal 
range 10-12 seconds) with mixing studies, activated 
partial thromboplastin time (APTT, normal range 26-
40 seconds) with mixing studies (Diagnostica Stago 
France kits, semi-automatic coagulation analyzer, 
STAGO, STart®). In the cases with normal 
coagulation tests, the clot solubility test in 5 M urea or 
1 % monochloroacetic acid environment was 
performed. Patients with the abnormal results of any of 
these tests, candidate for specific diagnostic assays. 
Plasma factor activity of coagulation factor was 
assayed by semi-automated coagulometer (ST-Art 
Diagnostica Stago, France). The severity of factor 
deficiencies were categorized according to the level of 
the specific factors obtained by factor assays (Table1). 
Von Willebrand factor (vWF) antigen and activity 
were evaluated by an ACL9000 analyzer (detection 
limit: 3.5%). Patients with undetectable levels of vWF 
considered as vWD type III. Platelet aggregation 
studies using platelet-rich plasma )PRP( with agonists 
such as ADP (final concentration of 20mol L/1), 
epinephrine (500 µmol /L), arachidonic acid (500 µg/ 
L), collagen (10 µg/ L), and ristocetin (1.5 µg/ L) were 
performed using turbidometric aggregometer (Pack 4, 
Helena Laboratories, Beaumont, TX, USA). Flow 
cytometric analysis for glycoprotein receptors on 




Among all investigated patients, 107 patients 
had different types of CBDs. HA with 60 cases (56%) 
was the most common bleeding disorder in the 
province. Among RBDs, FVIID with 64% frequency 
followed by FVD with a prevalence of 16% were the 
most common RBDs. Inhibitor screening in cases with 
an unsatisfactory response to replacement therapy 
showed only one case with HA developed an inhibitor. 
Among all patients, two cases affected by HA and 
vWD simultaneously. Out of 95 patients with 
coagulation disorders, 53.6%, 15.7% and 12.6% 
affected by the severe, moderate and mild degrees of 
disorders, respectively. The frequency of coagulation 
factor deficiencies was summarized in table 2. 
A total of 9 patients with vWD were identified. 
Out of these 9 patients, 1 of them diagnosed vWD type 
III and others had vWD type I. Considering inherited 
platelet disorders, 2 patients had type I Glanzmann 
thrombasthenia (GT). In one case of platelet disorders, 
it could not be classified in a specific group. By 
considering the estimated population of Kurdistan 
province (1.5 million), the prevalence of HA and HB 
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was 4 and 0.6 in 100000 males, respectively. The 
frequency of RBDs and platelet disorders was 
calculated 1.73 and 0.8 in 100000 residents. 
Discussion 
The incidence of CBDs based on countries and 
ethnicity is different. Iran as a Middle Eastern country 
Table 1: Demographic data of patients before surgery. 
 
Factor  Coagulation factor activity 
Severe Moderate Mild 
I Undetectable clot 0.1-1g/L >1g/L 
V Undetectable activity  ≤10% >10% 
VII <10% 10-20% >20% 
VIII <1% 1-5% >5% 
IX <1% 1-5% >5% 
X <10% 10-40% >40% 
XIII Abnormal clot solubility test - - 
 
Table 2: Prevalence of inherited coagulation factor deficiencies. 
 
Disorders Mild; n (%) Moderate; n (%) Severe; n (%) Not available; n (%) Total 
Common bleeding disorders  
HA 7(11.5) 9(15.5) 41(68) 3(5) 60 
HB  - 3(30) 4(40) 3(30) 10 
Rare bleeding disorders 
FID - - - 2(100) 2 
FVD 1(25) 1(25) 1(25) 1(25) 4 
FVIID 4(25) 2(12.5) 4(25) 6(37.5) 16 
FXD - - - 1(100) 1 
FXID - - - 1(100) 1 
FXIIID - - 1(100) - 1 
N: Number, HA: Hemophilia A, HB: Hemophilia B, FID: Fibrinogen deficiency, FVD: Factor V deficiency, FVIID: Factor VII 
deficiency, FXD: Factor X deficiency, FXIID: Factor XII deficiency, FXIIID: Factor XIII deficiency. 
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has a high rate of parental consanguinity, which results 
in increased frequency of inherited hemorrhagic 
disorders. Although the wide spectrum of studies 
conducted in this country, the exact distribution of 
these disorders has not established in all parts of the 
country. Among different provinces in Iran, Sistan and 
Baluchestan, southeast of Iran have the highest 
incidence of CBDs in Iran and most of the reports from 
Iran focus on this province. Based on the survey in 
2014 conducted by WFH in 107 countries, 176,211 
people with hemophilia (A and B) were identified. 
Iran, with 5,369 patients, has the ninth-largest 
hemophilia population (4,438 had HA and 931 had 
HB) (4). The number of patients with HA and HB in 
this study was 60 and 10, respectively which compared 
to another report from Kurdistan province (Sanandaj 
city) has lower HA but higher HB patients (HA: 104 
cases, HB: no case) (5).  
In a study conducted in Khorasan Razavi 
Province, 287 HA and 92 HB were reported. The 
prevalence of HA and HB in Khorasan Razavi 
Province was 10.29 per 100,000 and 3.30 per 100,000 
males, respectively which compared with the 
frequency of disease in the current study is much 
higher (6-8). Based on Dorgalaleh et al study, it seems 
the majority of patients registered in the hemophilia 
center of Tehran but the exact origin of them was not 
reported (8). Reported prevalence form Tehran 
Province, is 14 per 100 000 and 2.5 per 100 000 males 
of HA and HB, respectively (6). In the study conducted 
in South of Iran, 326 and 46 patients with HA and HB 
were reported, respectively. On this study, the 
prevalence of HA and HB was calculated as 7.2 and 1 
per 100000 residents (9). Most HA and HB patients 
had a severe form of the disease, including 68% for HA 
and 40% for HB. The findings of other studies from 
Iran are consistent with our study. In this report, the 
most common RBD is FVIID which is consistent with 
finding Karimi’s in 2009 (9).  In the study conducted 
in 2004 which investigated 750 Iranian patients with 
RDBs, Mannuci et al also reported FVIID as the most 
common RBD in Iran (10). These findings were 
different from reports of RBDs in the south east of Iran.  
According to different studies, Iran with about 
600 patients with FXIIID is the hotspot of disorder 
worldwide and southeast Iran had more than 400 
patients with this disorder but in the present study, only 
one case affected by FXIIID is diagnosed. This high 
frequency of FXIIID in southeast Iran makes this 
disorder the most common RBDs in Iran (11). FVD 
was the second RBDs in this study, which accounted 
for 15% of RBDs. This finding was similar to the 
report of Mansouritorghabeh et al from the North-
Eastern of Iran which report FVD as a second common 
RBD in this region (7).  
In a report from Southern and Southeast of Iran, 
FVD is fifth and third RBDs, respectively (9, 12).  A 
total of 9 patients had vWD and 2 and GT which was 
comparable with the result from the South of Iran. In 
that study on 55 patients, 41.8% affected by GT, 27.2% 
had Bernard Soulier Syndrome and the remaining had 
other platelet disorders (9). The study from North-
Eastern of Iran reported total of 88 cases with platelet 
disorders including 50 individuals (56.8%) with vWD 
and 38 (43.2%) with other platelet disorders (7).  
Conclusion 
Overall, due to the lack of diagnostic facilities 
and insufficient awareness of CBDs in developing 
countries in which governmental resources are 
restricted, health legislators need accurate data on 
prevalence and numbers of patients to plan and allot 
their budgets. Therefore determination the pattern, 
prevalence and distribution of various CBDs in 
countries, help ascertainment of global scenario of 
these type of disorders and important for health care 
planning and resource allocation. 
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